guest ::
| Home > Publications database > Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells. > print |
| Home > Publications database > Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells. > print |
| 001 | 179074 | ||
| 005 | 20240229145531.0 | ||
| 024 | 7 | _ | |a 10.1128/jvi.01705-21 |2 doi |
| 024 | 7 | _ | |a pmid:35262371 |2 pmid |
| 024 | 7 | _ | |a 0022-538X |2 ISSN |
| 024 | 7 | _ | |a 1070-6321 |2 ISSN |
| 024 | 7 | _ | |a 1098-5514 |2 ISSN |
| 024 | 7 | _ | |a altmetric:124379009 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00450 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Metz-Zumaran, Camila |b 0 |
| 245 | _ | _ | |a Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells. |
| 260 | _ | _ | |a Baltimore, Md. |c 2022 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1685612232_16286 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F140#LA:F140# / 2022 Apr 13;96(7):e0170521 |
| 520 | _ | _ | |a The coronavirus SARS-CoV-2 caused the COVID-19 global pandemic leading to 5.3 million deaths worldwide as of December 2021. The human intestine was found to be a major viral target which could have a strong impact on virus spread and pathogenesis since it is one of the largest organs. While type I interferons (IFNs) are key cytokines acting against systemic virus spread, in the human intestine type III IFNs play a major role by restricting virus infection and dissemination without disturbing homeostasis. Recent studies showed that both type I and III IFNs can inhibit SARS-CoV-2 infection, but it is not clear whether one IFN controls SARS-CoV-2 infection of the human intestine better or with a faster kinetics. In this study, we could show that type I and III IFNs both possess antiviral activity against SARS-CoV-2 in human intestinal epithelial cells (hIECs); however, type III IFN is more potent. Shorter type III IFN pretreatment times and lower concentrations were required to efficiently reduce virus load compared to type I IFNs. Moreover, type III IFNs significantly inhibited SARS-CoV-2 even 4 h postinfection and induced a long-lasting antiviral effect in hIECs. Importantly, the sensitivity of SARS-CoV-2 to type III IFNs was virus specific since type III IFN did not control VSV infection as efficiently. Together, these results suggest that type III IFNs have a higher potential for IFN-based treatment of SARS-CoV-2 intestinal infection compared to type I IFNs. IMPORTANCE SARS-CoV-2 infection is not restricted to the respiratory tract and a large number of COVID-19 patients experience gastrointestinal distress. Interferons are key molecules produced by the cell to combat virus infection. Here, we evaluated how two types of interferons (type I and III) can combat SARS-CoV-2 infection of human gut cells. We found that type III interferons were crucial to control SARS-CoV-2 infection when added both before and after infection. Importantly, type III interferons were also able to produce a long-lasting effect, as cells were protected from SARS-CoV-2 infection up to 72 h posttreatment. This study suggested an alternative treatment possibility for SARS-CoV-2 infection. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a SARS-CoV-2 |2 Other |
| 650 | _ | 7 | |a human intestinal epithelial cells |2 Other |
| 650 | _ | 7 | |a interferon |2 Other |
| 650 | _ | 7 | |a interferon lambda |2 Other |
| 650 | _ | 7 | |a intrinsic immune response |2 Other |
| 650 | _ | 7 | |a type III interferon |2 Other |
| 700 | 1 | _ | |a Kee, Carmon |0 P:(DE-He78)3fe1ba0b5fdc0317896f4587fa7af337 |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Doldan, Patricio |0 P:(DE-He78)51c7e0db09353baf8fff5d9a63da0abb |b 2 |e First author |u dkfz |
| 700 | 1 | _ | |a Guo, Cuncai |b 3 |
| 700 | 1 | _ | |a Stanifer, Megan L |0 P:(DE-He78)8c3dd76230733f354d346a2fbe8db355 |b 4 |u dkfz |
| 700 | 1 | _ | |a Boulant, Steeve |0 P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1128/jvi.01705-21 |g p. e01705-21 |0 PERI:(DE-600)1495529-5 |n 7 |p e0170521 |t Journal of virology |v 96 |y 2022 |x 0022-538X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:179074 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)3fe1ba0b5fdc0317896f4587fa7af337 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)51c7e0db09353baf8fff5d9a63da0abb |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 4 |6 P:(DE-He78)8c3dd76230733f354d346a2fbe8db355 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J VIROL : 2021 |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-17 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-17 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J VIROL : 2021 |d 2022-11-17 |
| 920 | 2 | _ | |0 I:(DE-He78)F140-20160331 |k F140 |l NWG Infection and Immune Sensing Dynamics |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F140-20160331 |k F140 |l NWG Infection and Immune Sensing Dynamics |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)F140-20160331 |k F140 |l NWG Infection and Immune Sensing Dynamics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F140-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|